Namida Lab

Executive Summary

Namida Lab is a US-based biotechnology company founded in 2018, pioneering non-invasive cancer screening and diagnostic tests using tear fluid. By leveraging proteomics and genomics to detect cancer biomarkers from ocular fluid, the company aims to make early cancer detection more accessible, affordable, and effective. Its innovative platform has the potential to disrupt traditional diagnostic methods, particularly for cancers that are currently difficult to detect early. While still in early stages, Namida Lab's approach addresses a significant unmet need in oncology diagnostics. The company is privately held and based in Fayetteville, Arkansas. Key upcoming catalysts include potential funding rounds, initial clinical data releases, and strategic partnerships. With a novel technology and a clear mission, Namida Lab is positioned for growth in the non-invasive diagnostics space, though it faces challenges in clinical validation and market adoption.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding60% success
• Q3 2026Preclinical Proof-of-Concept Data70% success
• TBDStrategic Partnership with Diagnostic Company40% success